Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Friday.

A number of other brokerages also recently issued reports on AMPH. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Needham & Company LLC increased their price target on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, December 1st. BMO Capital Markets increased their price target on shares of Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the stock a “market perform” rating in a report on Friday, November 10th. Piper Jaffray Companies set a $19.00 price target on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, October 22nd. Finally, Jefferies Group set a $19.00 price target on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, October 29th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $19.50.

Amphastar Pharmaceuticals (NASDAQ AMPH) opened at $19.37 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.86 and a debt-to-equity ratio of 0.13. The firm has a market cap of $890.56, a PE ratio of 129.13, a price-to-earnings-growth ratio of 1.36 and a beta of 1.69. Amphastar Pharmaceuticals has a 1 year low of $12.05 and a 1 year high of $19.95.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.05. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The firm had revenue of $57.90 million during the quarter, compared to analyst estimates of $57.23 million. During the same quarter last year, the business earned $0.14 earnings per share. The company’s quarterly revenue was down 9.8% on a year-over-year basis. sell-side analysts expect that Amphastar Pharmaceuticals will post -0.03 EPS for the current fiscal year.

In other news, Director Stephen B. Shohet sold 7,862 shares of the stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $18.37, for a total value of $144,424.94. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO William J. Peters sold 6,226 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $19.67, for a total transaction of $122,465.42. The disclosure for this sale can be found here. Over the last three months, insiders sold 72,787 shares of company stock worth $1,359,684. Insiders own 11.10% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Victory Capital Management Inc. raised its stake in Amphastar Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock valued at $100,000 after purchasing an additional 842 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Amphastar Pharmaceuticals in the second quarter valued at approximately $111,000. BNP Paribas Arbitrage SA raised its stake in Amphastar Pharmaceuticals by 58.2% in the second quarter. BNP Paribas Arbitrage SA now owns 10,545 shares of the company’s stock valued at $188,000 after purchasing an additional 3,880 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its stake in Amphastar Pharmaceuticals by 58.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 13,390 shares of the company’s stock valued at $239,000 after purchasing an additional 4,960 shares in the last quarter. Finally, Thrivent Financial For Lutherans raised its stake in Amphastar Pharmaceuticals by 7.2% in the second quarter. Thrivent Financial For Lutherans now owns 21,610 shares of the company’s stock valued at $386,000 after purchasing an additional 1,460 shares in the last quarter. 44.14% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece of content was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/01/21/amphastar-pharmaceuticals-amph-rating-increased-to-sell-at-bidaskclub.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.